valproic acid has been researched along with Fatty Liver with Encephalopathy in 23 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 of these patients developed toxic encephalopathy with hyperammonemia induced by VPA." | 1.27 | Treatment of epileptic patients with valproic acid does not modify plasma and urine short-chain-fatty acids. ( Arnetoli, G; Boncinelli, L; Campostrini, R; Paganini, M; Zaccara, G; Zappoli, R, 1983) |
| "This case study shows that Reye's syndrome causes altered valproate metabolism, consistent with the defective mitochondrial beta-oxidation of medium chain fatty acids, and suggests that valproic acid should not be used in the treatment of seizures in patients with this syndrome." | 1.27 | Altered metabolic profiles of valproic acid in a patient with Reye's syndrome. ( Fujii, H; Inoue, Y; Kitamura, K; Kuhara, T; Matsumoto, I; Matsumoto, M; Sakura, N; Shinka, T, 1985) |
| "She developed the typical features of Reye syndrome." | 1.26 | Decreased serum carnitine in valproate induced Reye syndrome. ( Böhles, H; Richter, K; Schäfer, H; Wagner-Thiessen, E, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (78.26) | 18.7374 |
| 1990's | 4 (17.39) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coulter, DL | 1 |
| Kim, CS | 1 |
| O'Tuama, LA | 1 |
| Mann, JD | 1 |
| Roe, CR | 1 |
| Sugimoto, T | 1 |
| Nishida, N | 1 |
| Yasuhara, A | 1 |
| Ono, A | 1 |
| Sakane, Y | 1 |
| Matsumura, T | 1 |
| Zaccara, G | 1 |
| Boncinelli, L | 1 |
| Paganini, M | 1 |
| Campostrini, R | 1 |
| Arnetoli, G | 1 |
| Zappoli, R | 1 |
| Berlin, CM | 1 |
| Powell-Jackson, PR | 1 |
| Tredger, JM | 1 |
| Williams, R | 1 |
| Young, RS | 1 |
| Bergman, I | 1 |
| Gang, DL | 1 |
| Richardson, EP | 1 |
| Keene, DL | 1 |
| Humphreys, P | 1 |
| Carpenter, B | 1 |
| Fletcher, JP | 1 |
| Böhles, H | 1 |
| Richter, K | 1 |
| Wagner-Thiessen, E | 1 |
| Schäfer, H | 1 |
| Seghieri, G | 1 |
| De Giorgio, LA | 1 |
| Innocenti, F | 1 |
| Pettiná, G | 1 |
| Zolfanelli, F | 1 |
| Apicella, P | 1 |
| Treem, WR | 1 |
| Trost, LC | 1 |
| Lemasters, JJ | 1 |
| Forget, PP | 1 |
| van Oosterhout, M | 1 |
| Bakker, JA | 1 |
| Wermuth, B | 1 |
| Vles, JS | 1 |
| Spaapen, LJ | 1 |
| Yamanouchi, H | 1 |
| Imataka, G | 1 |
| Gerber, N | 1 |
| Dickinson, RG | 1 |
| Harland, RC | 1 |
| Lynn, RK | 1 |
| Houghton, LD | 1 |
| Antonias, JI | 1 |
| Schimschock, JC | 1 |
| Ozawa, Y | 1 |
| Inagaki, Y | 1 |
| Yonei, Y | 1 |
| Tsukada, N | 1 |
| Okawa, H | 1 |
| Kiryu, Y | 1 |
| Oda, M | 1 |
| Lorz, U | 1 |
| Glötzner, FL | 1 |
| Murphy, JV | 1 |
| Marquardt, KM | 1 |
| Shug, AL | 1 |
| Coraggio, F | 1 |
| Angiulli, B | 1 |
| Carbone, M | 1 |
| Catalano, A | 1 |
| Costa, MR | 1 |
| Gargiulo, L | 1 |
| Gentile, B | 1 |
| Masetto, O | 1 |
| Pomponio, N | 1 |
| Scarpato, P | 1 |
| Matsuda, I | 1 |
| Ohtani, Y | 1 |
| Ninomiya, N | 1 |
| Klein, M | 1 |
| Wendt, U | 1 |
| Kuhara, T | 1 |
| Inoue, Y | 1 |
| Matsumoto, M | 1 |
| Shinka, T | 1 |
| Matsumoto, I | 1 |
| Kitamura, K | 1 |
| Fujii, H | 1 |
| Sakura, N | 1 |
| Izumi, T | 1 |
| Utsumi, H | 1 |
| Osawa, M | 1 |
| Fukuyama, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
5 reviews available for valproic acid and Fatty Liver with Encephalopathy
| Article | Year |
|---|---|
Advances in pediatric pharmacology and toxicology.
Topics: Animals; Anti-Bacterial Agents; Aspirin; Attention Deficit Disorder with Hyperactivity; Biological A | 1983 |
Hepatotoxicity to sodium valproate: a review.
Topics: Adolescent; Adult; Ammonia; Animals; Chemical and Drug Induced Liver Injury; Child; Child, Preschool | 1984 |
Inherited and acquired syndromes of hyperammonemia and encephalopathy in children.
Topics: Ammonia; Child; Hepatic Encephalopathy; Humans; Liver Diseases; Metabolism, Inborn Errors; Reye Synd | 1994 |
[Mitochondrial diseases due to drug toxicity].
Topics: Animals; Antibiotics, Antineoplastic; Aspirin; Humans; Mitochondria; Mitochondrial Diseases; Reye Sy | 2002 |
[Acute hepatic steatosis. Description of a clinical case of sodium valproate-induced acute hepatic steatosis].
Topics: Acute Disease; Adult; Biopsy; Child; Child, Preschool; Diagnosis, Differential; Fatty Liver; Fatty L | 1988 |
18 other studies available for valproic acid and Fatty Liver with Encephalopathy
| Article | Year |
|---|---|
Carnitine deficiency: a possible mechanism for valproate hepatotoxicity.
Topics: Carnitine; Child; Humans; Liver; Reye Syndrome; Valproic Acid | 1984 |
Carnitine deficiency: a possible mechanism for valproate hepatotoxicity.
Topics: Carnitine; Child; Humans; Liver; Reye Syndrome; Valproic Acid | 1984 |
Carnitine deficiency: a possible mechanism for valproate hepatotoxicity.
Topics: Carnitine; Child; Humans; Liver; Reye Syndrome; Valproic Acid | 1984 |
Carnitine deficiency: a possible mechanism for valproate hepatotoxicity.
Topics: Carnitine; Child; Humans; Liver; Reye Syndrome; Valproic Acid | 1984 |
Carnitine deficiency: a possible mechanism for valproate hepatotoxicity.
Topics: Carnitine; Child; Humans; Liver; Reye Syndrome; Valproic Acid | 1984 |
Carnitine deficiency: a possible mechanism for valproate hepatotoxicity.
Topics: Carnitine; Child; Humans; Liver; Reye Syndrome; Valproic Acid | 1984 |
Carnitine deficiency: a possible mechanism for valproate hepatotoxicity.
Topics: Carnitine; Child; Humans; Liver; Reye Syndrome; Valproic Acid | 1984 |
Carnitine deficiency: a possible mechanism for valproate hepatotoxicity.
Topics: Carnitine; Child; Humans; Liver; Reye Syndrome; Valproic Acid | 1984 |
Carnitine deficiency: a possible mechanism for valproate hepatotoxicity.
Topics: Carnitine; Child; Humans; Liver; Reye Syndrome; Valproic Acid | 1984 |
Effect of increasing carbon chain length on organic acid transport by the choroid plexus: a potential factor in Reye's syndrome.
Topics: 2,4-Dichlorophenoxyacetic Acid; 3-Hydroxybutyric Acid; Acids; Animals; Blood-Brain Barrier; Caproate | 1983 |
Reye-like syndrome associated with valproic acid.
Topics: Adolescent; Ammonia; Biopsy; Female; Humans; Liver; Liver Function Tests; Reye Syndrome; Status Epil | 1983 |
Treatment of epileptic patients with valproic acid does not modify plasma and urine short-chain-fatty acids.
Topics: Adolescent; Adult; Ammonia; Brain Diseases; Butyrates; Epilepsy; Fatty Acids; Female; Hemiterpenes; | 1983 |
Fatal Reye-like syndrome associated with valproic acid.
Topics: Child; Humans; Male; Reye Syndrome; Valproic Acid | 1980 |
Valproic acid producing a Reye-like syndrome.
Topics: Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemistry; | 1982 |
Decreased serum carnitine in valproate induced Reye syndrome.
Topics: Carnitine; Child, Preschool; Female; Humans; Reye Syndrome; Valproic Acid | 1982 |
[Description of a case of a syndrome similar to Reye's syndrome in a male adult undergoing treatment with valproic acid and phenobarbital].
Topics: Adult; Brain Diseases; Coma; Epilepsy, Tonic-Clonic; Fever; Humans; Male; Muscle Rigidity; Phenobarb | 1982 |
The mitochondrial permeability transition: a new pathophysiological mechanism for Reye's syndrome and toxic liver injury.
Topics: Animals; Aspirin; Carboxylic Acids; Chemical and Drug Induced Liver Injury; Cyclosporine; Male; Memb | 1996 |
Partial N-acetyl-glutamate synthetase deficiency masquerading as a valproic acid-induced Reye-like syndrome.
Topics: Ammonia; Child, Preschool; Glutamate Synthase; Humans; Liver Function Tests; Male; Reye Syndrome; Va | 1999 |
Reye-like syndrome associated with valproic acid therapy.
Topics: Chemical and Drug Induced Liver Injury; Child; Epilepsy; Female; Humans; Reye Syndrome; Valproic Aci | 1979 |
[An adult case of Reye like syndrome and acute pancreatitis associated with sodium valproate].
Topics: Acute Disease; Biopsy; Humans; Liver; Male; Middle Aged; Pancreatitis; Reye Syndrome; Valproic Acid | 1992 |
[Reye syndrome treated with valproic acid in association with varicella infection].
Topics: Adult; Aspirin; Carbamazepine; Chickenpox; Drug Therapy, Combination; Epilepsy; Humans; Male; Reye S | 1989 |
Valproic acid associated abnormalities of carnitine metabolism.
Topics: Carnitine; Child; Child, Preschool; Humans; Infant; Reye Syndrome; Valproic Acid | 1985 |
Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy.
Topics: Ammonia; Carnitine; Epilepsy; Humans; Infant; Intellectual Disability; Kidney; Metabolic Clearance R | 1986 |
[Reye-like syndrome following valproate therapy in an adult].
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Epilepsies, Partial; Humans; Male | 1988 |
Altered metabolic profiles of valproic acid in a patient with Reye's syndrome.
Topics: Biotransformation; Child; Chromatography, Gas; Female; Gas Chromatography-Mass Spectrometry; Glucuro | 1985 |
[A clinico-biochemical study of acute encephalopathy in patients treated with Ca-hopantenate].
Topics: Acute Disease; Adolescent; Adult; Age Factors; Blood Chemical Analysis; Brain Diseases; Child; Child | 1985 |